A prototype QSP model of the immune response to SARS-CoV-2 for community development / (Record no. 1854)

MARC details
000 -LEADER
fixed length control field 02657nam a22002657a 4500
003 - CONTROL NUMBER IDENTIFIER
control field DOH
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20201126141747.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201126b ||||| |||| 00| 0 eng d
245 02 - TITLE STATEMENT
Title A prototype QSP model of the immune response to SARS-CoV-2 for community development /
Statement of responsibility, etc. Wei Da [and five others]
520 3# - SUMMARY, ETC.
Summary, etc. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires the rapid development of efficacious treatments for patients with life-threatening coronavirus disease (COVID-19). Quantitative Systems Pharmacology (QSP) models are mathematical representations of pathophysiology for simulating and predicting the effects of existing or putative therapies. The application of model-based approaches, including QSP, have accelerated the development of some novel therapeutics. Nevertheless, the development of disease-scale mechanistic models can be a slow process, often taking years to be validated and considered mature. Furthermore, emerging data may make any QSP model quickly obsolete. We present a prototype QSP model to facilitate further development by the scientific community. The model accounts for the interactions between viral dynamics, the major host immune response mediators, and tissue damage and regeneration. The immune response is determined by viral activation of innate and adaptive immune processes that regulate viral clearance and cell damage. The prototype model captures two physiologically relevant outcomes following infection: a 'healthy' immune response that appropriately defends against the virus, and an uncontrolled alveolar inflammatory response that is characteristic of acute respiratory distress syndrome. We aim to significantly shorten the typical QSP model development and validation timeline by encouraging community use, testing, and refinement of this prototype model. It is our expectation that the model will be further advanced in an open science approach; i.e. by multiple contributions towards a validated quantitative platform in an open forum, with the ultimate goal of informing and accelerating the development of safe and effective treatment options for patients.
580 ## - LINKING ENTRY COMPLEXITY NOTE
Linking entry complexity note In: CPT Pharmacometrics Syst Pharmacol . 2020 Nov 20. <br/>doi: 10.1002/psp4.12574.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunity, Active
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Inflammation
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term COVID-19
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Viral dynamics
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Dai, Wei
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Rao, Rohit
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sher, Anna
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Tania, Nessy
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Musante, Cynthia J.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Allen, Richard
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12574">https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12574</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type COVID 19 Resource
999 ## -
-- 1854
-- 1854
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
        DOH Central Library DOH Central Library Electronic Resource Section 11/26/2020   COVID-19-000079 D0001C000079 11/26/2020 11/26/2020 COVID 19 Resource